目的 分析寧夏回族自治區(qū)人民醫(yī)院新型抗腫瘤藥物的使用情況，為合理應(yīng)用及規(guī)范化管理提供參考。方法 對2019—2022年寧夏回族自治區(qū)人民醫(yī)院新型抗腫瘤藥物的藥品規(guī)格、年銷售金額、用藥頻度（DDDs）、日均費用（DDC）以及排序比（B/A）進行統(tǒng)計分析。結(jié)果 2019—2022年，寧夏回族自治區(qū)人民醫(yī)院新型抗腫瘤藥物品規(guī)逐年增加。2022年銷售金額激增，較2019年增長3.2倍。大多數(shù)藥物DDDs逐年上升，21種藥物DDC較2021年下降，吉非替尼、伊馬替尼使用頻率高，DDC低，B/A遠大于1，顯示出良好的同步性。結(jié)論 隨著新醫(yī)改政策的實施，寧夏回族自治區(qū)人民醫(yī)院新型抗腫瘤藥物品種增多、使用量逐漸增加，藥物價格下降，新型抗腫瘤藥的使用基本合理。

Objective To analyze the application situation of new antitumor drugs in the People’s Hospital of Ningxia Hui Autonomous Region, and to provide references for the rational use and standardized management. Methods The new antitumor drugs in People’s Hospital of Ningxia Hui Autonomous Region from 2019 to 2022 were analyzed statistically of the drug specifications, annual consumption sum, medication frequency (DDDs), average daily cost (DDC), and ranking ratio (B/A). Results From 2019 to 2022, the regulations of new antitumor drugs in People’s Hospital of Ningxia Hui Autonomous Region increased year by year. Consumption sum increased sharply in 2022, nearly 3.2 times compared with 2019. The DDDs of most drugs increased year by year, and the DDC of twenty-one drugs decreased compared with 2021. Gefitinib and imatinib were used with high frequency, low daily cost, and B/A was much higher than 1, shows good synchronization. Conclusion With the implementation of the new medical reform policies, the variety and use of new antitumor drugs in People’s Hospital of Ningxia Hui Autonomous Region have increased gradually, and the price has decreased. The utilization of new antitumor drugs is basically reasonable.

R978.7